The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.
The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...
The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non-addictive alternative.
The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...
The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback